Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Decision brief
Answer first · skim in under a minute
Kazia Therapeutics has announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and financial leadership within the biotech sector.
Kazia Therapeutics appointed James Levine as chief financial officer effective June 1, 2026, adding oncology-focused finance and deal leadership as the clinical-stage company advances paxalisib and related programs.
Contents12 sections
Key Takeaways
- Appointment effective June 1, 2026; announced via PR Newswire and Form 6-K on June 2.
- Base salary US$475,000 with 40% target bonus (prorated for 2026).
- Options over 200,000 ADSs; one-third vest at start, remainder annually; forfeit if voluntary exit before one year.
- Levine previously CFO of Cardiff Oncology and Cidara Therapeutics.
Who is James Levine and what is his oncology finance background?
Levine brings more than two decades across investment banking and public-biotech finance roles.
He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company.
Earlier, as CFO of Cidara Therapeutics, he helped structure a $568 million Mundipharma licensing collaboration and a $780 million Janssen global partnership.
What are the key terms in Kazia's employment agreement?
Kazia's June 2, 2026 Form 6-K discloses a US$475,000 annual base salary.
Target bonus is 40% of base salary, prorated for 2026.
Subject to Board approval, Levine will receive options over 200,000 American Depositary Shares.
- Base: US$475,000
- Bonus target: 40%
- Options: 200,000 ADSs
How do the equity vesting rules align incentives?
One-third of the ADS options vest at employment commencement.
The remaining two-thirds vest in equal yearly installments thereafter.
All options are forfeited upon voluntary departure before completing one year of employment.
Why does this hire matter for Kazia's oncology strategy?
CEO John Friend said Levine's transaction experience will help capitalize on momentum around paxalisib and the broader pipeline.
The company's PR Newswire release frames the hire as support for the next phase of oncology growth.
For a clinical-stage issuer, CFO credibility often precedes financing, partnering, or registrational spend decisions.
Where can investors track Kazia's clinical programs?
Public trial listings for Kazia-sponsored studies appear on ClinicalTrials.gov.
Paxalisib remains the central oncology asset investors associate with the ticker KZIA.
Upcoming registrational planning will test whether the new finance leader can fund timelines without repeated dilutive emergencies.
What remains uncertain after the appointment?
A CFO hire does not change clinical probability of success for paxalisib.
Option grants require Board approval and may dilute ADS holders depending on final terms.
Investors should wait for subsequent filings for any updated cash runway or financing guidance.
How does Levine's banking background map to a micro-cap oncology issuer?
Twelve years as a Goldman Sachs managing director advising U.S. and European biotech clients on financings and mergers is unusual depth for a company of Kazia's scale.
That background can matter when negotiating structure on follow-on offerings, registered directs, or regional licensing for paxalisib.
It also brings pattern recognition for when a clinical story is ready for a larger strategic partner versus another public raise.
What should shareholders watch in the next two quarters?
Beyond the symbolic CFO announcement, investors need updated cash runway, burn, and any non-dilutive partnering plans tied to oncology milestones.
The one-year forfeiture cliff on ADS options is a retention feature; it does not by itself guarantee operational continuity.
Clinical readouts and trial-site execution will still dominate valuation even with stronger finance leadership in place.
Track Form 6-K and press releases for any amendment to the employment terms or related arrangements after June 2026.
In short, the Levine appointment upgrades Kazia's finance bench for oncology partnering, but clinical execution on paxalisib remains the value driver investors must still underwrite.
Kazia shareholders should also compare Levine's $475,000 base and 200,000 ADS option grant with peer micro-cap oncology CFO packages before assuming the hire alone de-risks funding.
Those compensation details are already public in the June 2, 2026 Form 6-K and help frame retention incentives through 2027.
Related NovaPharma coverage
- Celcuity gedatolisib FDA path
- Revolution Medicines pancreatic cancer results
- Biopharma news week of June 2026
Frequently Asked Questions
Who did Kazia appoint as CFO?
Kazia Therapeutics appointed James Levine as Chief Financial Officer effective June 1, 2026. The company announced the appointment on June 2, 2026.
What is Levine's compensation package?
According to Kazia's Form 6-K, Levine receives a US$475,000 base salary, a 40% target annual bonus prorated for 2026, and options over 200,000 ADSs subject to Board approval.
Why does the CFO hire matter for Kazia's oncology pipeline?
Kazia is advancing paxalisib and other oncology assets. Levine previously led major licensing deals at Cidara, including partnerships valued at $568 million and $780 million, experience the company says it wants as milestones approach.
Primary Sources
Kazia Therapeutics pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…